104774-88-1

Basic information

• Product Name: 4-(3-FLUORO-PHENYL)-PIPERIDINE
• Synonyms: 4-(3-FLUORO-PHENYL)-PIPERIDINE;Piperidine, 4-(3-fluorophenyl)-
• CAS NO: 104774-88-1
• Molecular Formula: C₁₁H₁₄FN
• Molecular Weight: 179.23
• Mol File: 104774-88-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 256℃
• Flash Point: 108℃
• Appearance: Gray-white power
• Density: 1.048
• Vapor Pressure: 0.0163mmHg at 25°C
• Refractive Index: 1.506
• PKA: 10.12±0.10(Predicted)
• CAS DataBase Reference: 4-(3-FLUORO-PHENYL)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-FLUORO-PHENYL)-PIPERIDINE(104774-88-1)
• EPA Substance Registry System: 4-(3-FLUORO-PHENYL)-PIPERIDINE(104774-88-1)

Safety Data

• Hazard Codes: Xi
• Statements: 52
• HazardClass: IRRITANT
• Hazardous Substances Data: 104774-88-1(Hazardous Substances Data)

Usage

General Description

4-(3-Fluoro-phenyl)-piperidine is a chemical compound, specifically a derivative of piperidine. Piperidine is a widely used building block in the synthesis of organic compounds such as pharmaceuticals, polymers, and fine chemicals. The substitution of one hydrogen atom of the piperidine's ring with a 3-fluoro-phenyl group results in 4-(3-Fluoro-phenyl)-piperidine. The presence of the fluorine atom can affect the compound's reactivity, polarity, and other chemical properties. The exact properties and potential uses of this specific derivative depend on the particular reactions where it is involved. Like many organic compounds with a nitrogen-containing ring, it should be handled with care due to potential toxicity or reactivity.

InChI:InChI=1/C11H14FN/c12-11-3-1-2-10(8-11)9-4-6-13-7-5-9/h1-3,8-9,13H,4-7H2

Upstream product

• 1086398-00-6 tert-butyl 4-(3-fluorophenyl)piperidine-1-carboxylate 
• 358722-19-7 4-(3-fluoro-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 768-35-4 3-fluorophenylboronic acid 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 694-05-3 1,2,3,6-tetrahydropyridine 
• 462-06-6 fluorobenzene 

Downstream Products

• 107336-05-0 2-{2-[4-(3-Fluoro-phenyl)-piperidin-1-yl]-ethoxy}-benzaldehyde 
• 107336-12-9 2-{3-[4-(3-Fluoro-phenyl)-piperidin-1-yl]-propoxy}-benzaldehyde 
• 107335-63-7 2-(2-{2-[4-(3-Fluoro-phenyl)-piperidin-1-yl]-ethoxy}-phenyl)-thiazolidine-3-carboxylic acid methylamide 
• 107335-68-2 2-(2-{3-[4-(3-Fluoro-phenyl)-piperidin-1-yl]-propoxy}-phenyl)-thiazolidine-3-carboxylic acid methylamide 
• 107335-80-8 2-(2-{2-[4-(3-Fluoro-phenyl)-piperidin-1-yl]-ethoxy}-phenyl)-thiazolidine-3-carbothioic acid methylamide 
• 107335-85-3 2-(2-{3-[4-(3-Fluoro-phenyl)-piperidin-1-yl]-propoxy}-phenyl)-thiazolidine-3-carbothioic acid methylamide 
• 1254948-78-1 C₁₇H₁₅F₇N₂OS 
• 1323406-05-8 3-(4-[4-[4-(3-FLUORO-PHENYL)-PIPERIDIN-1-YLMETHYL]-BENZYLOXY]-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE 

Relevant articles and documents

Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents

Epilepsy is a kind of disease with complicated pathogenesis. KCNQ (Kv7) is a voltage dependent potassium channel that is mostly associated with epilepsy and thus becomes an important target in the treatment of epilepsy. In this paper, a series of substituted piperidine derivatives targeting KCNQ were designed and synthesized by using scaffold hopping and active substructure hybridization. Compounds were evaluated by fluorescence-based thallium influx assay, Rb+ flow assay and electrophysiological patch-clamp assay. Results showed that some compounds possessed more potent potassium channel opening activity than Retigabine. More significantly, compound 11 was found to have good pharmacokinetic profiles in vivo.

Potent heteroarylpiperidine and carboxyphenylpiperidine 1-alkyl-cyclopentane carboxamide CCR2 antagonists

This report describes replacement of the 4-(4-fluorophenyl)piperidine moiety in our CCR2 antagonists with 4-heteroaryl piperidine and 4-(carboxyphenyl)-piperidine subunits. Some of the resulting analogs retained potency in our CCR2 binding assay and had i